Nonalcoholic fatty liver treatment

Therapeutic effects of losartan in nonalcoholic steatohepatitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161210031316N2

Enrollment

Registered

2018-02-13

Start date

2016-11-01

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NASH. Nonalcoholic steatohepatitis (NASH)

Interventions

Intervention 1: Control group: Placebo for 6 month. Intervention 2: Intervention group 1: Losartan (abidi: lostar) 25 mg daily for 6 month.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Non-alcoholic steatohepatitis and liver enzymes are based on indicators of liver function and ultrasound Age over 18 years

Exclusion criteria

Exclusion criteria: alcohol intake of angiotensin receptor antagonists use of angiotensin converting enzyme inhibitors resistance-resistant hypertension Uncontrolled Diabetes hypotension serious interactions with other patient medications other causes of liver steatosis

Design outcomes

Primary

Measure	Time frame
Serum creatinin. Timepoint: Measurement of serum creatinine at baseline (before intervention) and 7 days and 1.3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Serum potasium. Timepoint: Serum potassium measurements at the beginning of the study (before intervention) and 7 days and 1.3.6 months after the start of losartan administration. Method of measurement: by Laboratory.;Serum Alkaline phosphatase. Timepoint: Measurement of serum alkaline phosphatase at baseline (before intervention) and 3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Serum Alanine aminotransferase. Timepoint: Measurement of serum alanine aminotransferase at baseline (before intervention) and 3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Serum Aspartate aminotransferase. Timepoint: Measurement of serum aspartate aminotransferase at baseline (before intervention) and 3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Blood pressure. Timepoint: Blood pressure measurement at the beginning of the study (before the intervention) and 1,2,3,4,5,6 months after the start of losartan administration. Method of measurement: Barometer.;Body Mass Index. Timepoint: Measuring the body mass index at the beginning of the study (before the intervention) and 3.6 months after starting the administration of losartan. Method of measurement: Meter , Balance.;Liver ultrasound indices. Timepoint: Measurement of liver ultrasonography at the beginning of the study (before the intervention) and 3.6 months after the start of administration of losartan. Method of measurement: Sonography.	—

Measure

Time frame

Serum creatinin. Timepoint: Measurement of serum creatinine at baseline (before intervention) and 7 days and 1.3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Serum potasium. Timepoint: Serum potassium measurements at the beginning of the study (before intervention) and 7 days and 1.3.6 months after the start of losartan administration. Method of measurement: by Laboratory.;Serum Alkaline phosphatase. Timepoint: Measurement of serum alkaline phosphatase at baseline (before intervention) and 3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Serum Alanine aminotransferase. Timepoint: Measurement of serum alanine aminotransferase at baseline (before intervention) and 3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Serum Aspartate aminotransferase. Timepoint: Measurement of serum aspartate aminotransferase at baseline (before intervention) and 3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Blood pressure. Timepoint: Blood pressure measurement at the beginning of the study (before the intervention) and 1,2,3,4,5,6 months after the start of losartan administration. Method of measurement: Barometer.;Body Mass Index. Timepoint: Measuring the body mass index at the beginning of the study (before the intervention) and 3.6 months after starting the administration of losartan. Method of measurement: Meter , Balance.;Liver ultrasound indices. Timepoint: Measurement of liver ultrasonography at the beginning of the study (before the intervention) and 3.6 months after the start of administration of losartan. Method of measurement: Sonography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzim Forozan

Arak University of Medical Sciences

a.forozan@arakmu.ac.ir+98 86 3417 3639

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026